Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024
Vericel (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's President and CEO, Nick Colangelo, along with CFO Joe Mara, will engage in a fireside chat on Friday, September 6, 2024, at 1:05 p.m. ET.
This presentation offers investors and interested parties an opportunity to gain insights into Vericel's operations, strategies, and market position. The event will be accessible via webcast on the Investor Relations section of Vericel's website, allowing for widespread viewing and potential increased investor engagement.
Vericel (NASDAQ:VCEL), un leader nelle terapie avanzate per la medicina sportiva e la cura delle gravi ustioni, ha annunciato la sua partecipazione alla 22a Conferenza Annuale sulla Salute Globale di Morgan Stanley. Il Presidente e CEO dell'azienda, Nick Colangelo, insieme al CFO Joe Mara, parteciperanno a una chiacchierata informale venerdì 6 settembre 2024, alle 13:05 ora ET.
Questa presentazione offre agli investitori e agli interessati un'opportunità per acquisire informazioni sulle operation di Vericel, sulle strategie e sulla posizione di mercato. L'evento sarà accessibile tramite webcast nella sezione Relazioni con gli Investitori del sito web di Vericel, consentendo una visione diffusa e un potenziale aumento del coinvolgimento degli investitori.
Vericel (NASDAQ:VCEL), un líder en terapias avanzadas para la medicina deportiva y el cuidado de quemaduras graves, ha anunciado su participación en la 22ª Conferencia Anual de Salud Global de Morgan Stanley. El Presidente y CEO de la compañía, Nick Colangelo, junto con el CFO Joe Mara, participarán en una charla informal el viernes 6 de septiembre de 2024, a la 1:05 p.m. ET.
Esta presentación ofrece a los inversores y partes interesadas la oportunidad de obtener información sobre las operaciones, estrategias y posición de mercado de Vericel. El evento será accesible a través de una transmisión web en la sección de Relaciones con Inversores del sitio web de Vericel, permitiendo una visualización amplia y un posible aumento en el compromiso de los inversores.
Vericel (NASDAQ:VCEL)는 스포츠 의학 및 중증 화상 치료를 위한 첨단 치료의 선두주자로, 모건 스탠리 제22회 글로벌 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. 회사의 사장 겸 CEO인 Nick Colangelo와 CFO인 Joe Mara는 2024년 9월 6일 금요일 오후 1시 5분 ET에 화로 옆 대화에 참여할 예정입니다.
이 발표는 투자자 및 관심 있는 당사자들에게 Vericel의 운영, 전략 및 시장 위치에 대한 통찰을 얻을 수 있는 기회를 제공합니다. 이 행사는 Vericel 웹사이트의 투자자 관계 섹션을 통해 웹캐스트로 제공되어 널리 시청할 수 있고 투자자 참여를 증가시킬 가능성도 있습니다.
Vericel (NASDAQ:VCEL), un leader dans les thérapies avancées pour la médecine sportive et le soin des brûlures sévères, a annoncé sa participation à la 22ème Conférence Annuelle Mondiale sur la Santé de Morgan Stanley. Le Président et CEO de la société, Nick Colangelo, ainsi que le CFO Joe Mara, participeront à une discussion informelle le vendredi 6 septembre 2024, à 13h05 ET.
Cette présentation offre aux investisseurs et aux parties intéressées l'opportunité d'obtenir des informations sur les opérations, stratégies et position sur le marché de Vericel. L'événement sera accessible par webcast dans la section des Relations avec les Investisseurs du site Web de Vericel, permettant une large diffusion et un engagement accru des investisseurs.
Vericel (NASDAQ:VCEL), ein führendes Unternehmen für fortschrittliche Therapien in der Sportmedizin und bei schwerer Brandverletzungsbehandlung, hat seine Teilnahme an der 22. jährlichen Global Healthcare Conference von Morgan Stanley angekündigt. Der Präsident und CEO des Unternehmens, Nick Colangelo, wird gemeinsam mit CFO Joe Mara am Freitag, den 6. September 2024, um 13:05 Uhr ET an einem informellen Gespräch teilnehmen.
Diese Präsentation bietet Investoren und Interessierten die Möglichkeit, Einblicke in die Geschäftsabläufe, Strategien und Marktposition von Vericel zu gewinnen. Die Veranstaltung wird über einen Webcast im Bereich Investor Relations auf der Website von Vericel zugänglich sein, was eine breite Sichtbarkeit und potenziell ein erhöhtes Engagement von Investoren ermöglicht.
- None.
- None.
CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference at 1:05 p.m. ET on Friday, September 6, 2024.
A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2024 Vericel Corporation. All rights reserved.
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
Media Contact:
Julie Downs
media@vcel.com
FAQ
When is Vericel (VCEL) presenting at the Morgan Stanley Global Healthcare Conference?
Who will be representing Vericel (VCEL) at the Morgan Stanley conference?
How can I watch Vericel's (VCEL) presentation at the Morgan Stanley conference?
What markets does Vericel (VCEL) specialize in?
